Breast cancer classification by proteomic technologies: Current state of knowledge

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 129-138

  Lam, S W ^a   Jimenez, C R ^a   Boven, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Breast cancer; Molecular subtypes; Proteomics; Review

Indexed keywords

BIOLOGICAL MARKER; CD147 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; RANTES; SARACATINIB; TAMOXIFEN; TRASTUZUMAB;

BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; ISOTOPE LABELING; MASS SPECTROMETER; METASTASIS POTENTIAL; MOLECULAR PATHOLOGY; PREVALENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VALIDATION PROCESS;

BIOMARKERS; BREAST CANCER; MOLECULAR SUBTYPES; PROTEOMICS; REVIEW;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84887108577     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.006     Document Type: Review

References (72)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Smith B.D., Smith G.L., Hurria A., et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
3. Sørlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
4. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
5. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
6. Badve S., Dabbs D.J., Schnitt S.J., et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011, 24:157-167.
7. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7:e1000279.
8. Fountzilas G., Dafni U., Bobos M., et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One 2012, 7:e37946.
9. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
10. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
11. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.
12. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295:2492-2502.
13. O'Brien K.M., Cole S.R., Tse C.K., et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16:6100-6110.
14. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23.
15. Altelaar A.F., Munoz J., Heck A.J. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet 2013, 14:35-48.
16. Piersma S.R., Fiedler U., Span S., et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 2010, 9:1913-1922.
17. Mallick P., Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol 2010, 28:695-709.
18. Pham T.V., Piersma S.R., Oudgenoeg G., et al. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn 2012, 12:343-359.
19. Hall D.A., Ptacek J., Snyder M. Protein microarray technology. Mech Ageing Dev 2007, 128:161-167.
20. Sutandy F.X., Qian J., Chen C.S., et al. Overview of protein microarrays. Curr Protoc Protein Sci 2013, 10.1002/0471140864.ps2701s72.
21. Mueller C., Liotta L.A., Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 2010, 4:461-481.
22. Berrade L., Garcia A.E., Camarero J.A. Protein microarrays: novel developments and applications. Pharm Res 2011, 28:1480-1499.
23. Picotti P., Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012, 9:555-566.
24. Gillette M.A., Carr S.A. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods 2013, 10:28-34.
25. Arvold N.D., Taghian A.G., Niemierko A., et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011, 29:3885-3891.
26. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
27. Weitzel L.R., Byers T., Allen J., et al. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat 2010, 124:297-305.
28. Sahab Z.J., Man Y.G., Semaan S.M., et al. Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype. Clin Exp Metastasis 2010, 27:493-503.
29. Cha S., Imielinski M.B., Rejtar T., et al. In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology. Mol Cell Proteomics 2010, 9:2529-2544.
30. Traub F., Jost M., Hess R., et al. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 2006, 86:246-253.
31. Moody T.W. Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann N Y Acad Sci 2007, 1112:297-304.
32. Neubauer H., Clare S.E., Wozny W., et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10:R85.
33. Ahmed I.S., Rohe H.J., Twist K.E., et al. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010, 285:24775-24782.
34. Rezaul K., Thumar J.K., Lundgren D.H., et al. Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer 2010, 1:251-271.
35. Semaan S.M., Wang X., Marshall A.G., et al. Identification of potential glycoprotein biomarkers in estrogen receptor positive (ER+) and negative (ER-) human breast cancer tissues by LC-LTQ/FT-ICR mass spectrometry. J Cancer 2012, 3:269-284.
36. Schaaij-Visser T.B., de Wit M., Lam S.W., et al. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 2013, 10.1016/j.bbapap.2013.01.029.
37. Pavlou M.P., Dimitromanolakis A., Diamandis E.P. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. Proteomics 2013, 13:1083-1095.
38. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803.
39. Umar A., Kang H., Timmermans A.M., et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 2009, 8:1278-1294.
40. Hodgkinson V.C., Agarwal V., Elfadl D., et al. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. J Proteomics 2012, 75:2745-2752.
41. Hodgkinson V.C., ELFadl D., Agarwal V., et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. J Proteomics 2012, 75:1276-1283.
42. Voduc K.D., Cheang M.C., Tyldesley S., et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
43. Durán M.C., Vega F., Moreno-Bueno G., et al. Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. Proteomics Clin Appl 2008, 2:1313-1326.
44. Zhang D., Tai L.K., Wong L.L., et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005, 4:1686-1696.
45. Zhang D.H., Tai L.K., Wong L.L., et al. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005, 5:1797-1805.
46. Zhang D., Tai L.K., Wong L.L., et al. Proteomic characterization of differentially expressed proteins in breast cancer: Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu status. Proteomics Clin Appl 2008, 2:99-107.
47. Dong D., Ni M., Li J., et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008, 68:498-505.
48. Beshir A.B., Ren G., Magpusao A.N., et al. Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 2010, 299:137-149.
49. Lee E., Nichols P., Spicer D., et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006, 66:7849-7853.
50. Lee E., Nichols P., Groshen S., et al. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 2011, 128:726-731.
51. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 14:2593-2600.
52. Yun J., Frankenberger C.A., Kuo W.L., et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 2011, 30:4500-4514.
53. Georgoulias V., Bozionelou V., Agelaki S., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 2012, 23:1744-1750.
54. Bose R., Molina H., Patterson A.S., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA 2006, 103:9773-9778.
55. Rexer B.N., Ham A.J., Rinehart C., et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
56. Liu L., Greger J., Shi H., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009, 69:6871-6878.
57. Boyer A.P., Collier T.S., Vidavsky I., et al. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Proteomics 2012, 12:180-193.
58. de Ronde J.J., Hannemann J., Halfwerk H., et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010, 119:119-126.
59. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948.
60. Warmoes M., Jaspers J.E., Pham T.V., et al. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics 2012, 11:M111.
61. Charpin C., Giusiano S., Secq V., et al. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol 2009, 34:983-993.
62. Greenwood C., Metodieva G., Al-Janabi K., et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics 2011, 75:3031-3040.
63. Sun B., Zhang S., Zhang D., et al. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008, 14:7050-7059.
64. Hochgräfe F., Zhang L., O'Toole S.A., et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 2010, 70:9391-9401.
65. Garcia S., Dales J.P., Charafe-Jauffret E., et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007, 38:830-841.
66. Nakshatri H., Qi G., You J., et al. Intrinsic subtype-associated changes in the plasma proteome in breast cancer. Proteomics Clin Appl 2009, 3:1305-1313.
67. Pitteri S.J., Amon L.M., Busald B.T., et al. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res 2010, 70:8598-8606.
68. Amon L.M., Pitteri S.J., Li C.I., et al. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Res 2012, 72:1935-1942.
69. Gonzalez R.M., Daly D.S., Tan R., et al. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 2011, 20:1543-1551.
70. Li C.I., Mirus J.E., Zhang Y., et al. Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the women's health initiative observational study. Breast Cancer Res Treat 2012, 135:611-618.
71. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747.
72. Schulz D.M., Bollner C., Thomas G., et al. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 2009, 8:3430-3438.